Quick Answer
Monte Rosa Therapeutics, Inc. reported R&D Expense of $141.50 million for fiscal year 2025.
Monte Rosa Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $141.50M | +16.4% |
| 2024 | $121.56M | +9.2% |
| 2023 | $111.27M | +30.8% |
| 2022 | $85.06M | +48.8% |
| 2021 | $57.16M | +138.1% |
| 2020 | $24.00M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $36.68M | +32.8% | +19.7% |
| June 30, 2025 | $30.65M | +9.3% | -4.8% |
| March 31, 2025 | $32.19M | +19.1% | +16.6% |
| September 30, 2024 | $27.62M | -2.4% | -1.6% |
| June 30, 2024 | $28.05M | -3.5% | +3.8% |
| March 31, 2024 | $27.03M | +1.0% | -4.5% |
| September 30, 2023 | $28.31M | +32.6% | -2.6% |
| June 30, 2023 | $29.08M | +38.9% | +8.7% |
- Monte Rosa Therapeutics, Inc. showed an increase of +16.4% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Monte Rosa Therapeutics, Inc.’s r&d expense has grown by 489.5% (from $24.00 million to $141.50 million).
- The most recent figure is from Monte Rosa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: